{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:01:15Z","timestamp":1760551275333,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Compared to clopidogrel, prasugrel has a lower incidence of ischemic events following percutaneous coronary intervention (PCI) because of an early reduction during the acute phase in P2Y12 reaction units (PRU). The objective of this study was to compare the antiplatelet effect and vascular endothelial function of both drugs during the chronic phase after PCI. Patients who had undergone PCI and were confirmed to have no restenosis by follow-up coronary angiography under dual anti-platelet therapy with clopidogrel (75\u00a0mg\/day) and aspirin (100\u00a0mg\/day) were randomized to either continue clopidogrel or switch to prasugrel (3.75\u00a0mg\/day). At baseline, prior to randomization we determined the CYP2C19 genotype. At the baseline and 24\u00a0weeks after randomization, the P2Y12 reactivity unit (PRU) was measured using the VerifyNow\u2122 P2Y12 assay. Endothelial function was evaluated by flow-mediated vasodilation (FMD) and reactive hyperemia peripheral arterial tonometry (RH-PAT), while and circulating CD34+\/CD133+\/CD45<jats:sup>low<\/jats:sup> progenitor cells were measured by flow cytometric analysis. Serum high-sensitivity C-reactive protein (hsCRP) level was also measured. The PRU was reduced significantly in the prasugrel group (<jats:italic>P<\/jats:italic>\u2009=\u20090.0008), especially in patients who were intermediate or poor metabolizers based on the CYP2C19 genotype (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). This reduction was not observed in the clopidogrel group. The number of CD34+\/CD133+\/CD45<jats:sup>low<\/jats:sup> cells increased in the clopidogrel group (<jats:italic>P<\/jats:italic>\u2009=\u20090.008), but not in the prasugrel group. The hsCRP, FMD and reactive hyperemia index measured by RH-PAT did not change in either group. Prasugrel is potentially better than clopidogrel for preventing thrombotic events, although clopidogrel may have an advantage over prasugrel in terms of preventing atherosclerotic events. Proper use of thienopyridine drugs based on the CYP2C19 genotype has promising clinical potential.<\/jats:p>","DOI":"10.1007\/s00380-020-01714-w","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T16:02:55Z","timestamp":1603900975000},"page":"442-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of switching from clopidogrel to prasugrel at the chronic phase after coronary stenting on antiplatelet action and vascular endothelial function: Switch-Pras study"],"prefix":"10.1007","volume":"36","author":[{"given":"Taiki","family":"Masuyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-0799","authenticated-orcid":false,"given":"Masashi","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Waku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keijiro","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Yazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shichiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"1714_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000357399","volume":"127","author":"D Alexopoulos","year":"2014","unstructured":"Alexopoulos D (2014) P2Y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa. Cardiology 127:211\u2013219","journal-title":"Cardiology"},{"key":"1714_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF03256587","volume":"8","author":"JP Depta","year":"2008","unstructured":"Depta JP, Bhatt DL (2008) Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance. Am J Cardiovasc Drugs 8:91\u2013112","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2 Suppl","key":"1714_CR3","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.ahj.2008.06.005","volume":"156","author":"DJ Angiolillo","year":"2008","unstructured":"Angiolillo DJ, Bates ER, Bass TA (2008) Clinical profile of prasugrel, a novel thienopyridine. Am Heart J 156(2 Suppl):S16\u2013S22","journal-title":"Am Heart J"},{"key":"1714_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","volume":"78","author":"S Saito","year":"2014","unstructured":"Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Nakamura M (2014) Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT\u2013ACS study. Circ J 78:1684\u20131692","journal-title":"Circ J"},{"key":"1714_CR5","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1253\/circj.CJ-14-0266","volume":"78","author":"T Isshiki","year":"2014","unstructured":"Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Saito S, PRASFIT-Elective Investigators (2014) Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J 78:2926\u20132634","journal-title":"Circ J"},{"key":"1714_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1253\/circj.CJ-19-0645","volume":"84","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Kitazono T, Kozuma K, Sekine T, Nakamura S, Shiosakai K, Iizuka T (2019) Prasugrel for Japanese patients with ischemic heart disease in long-term clinical practice (PRASFIT-Practice II): 1-year follow-up results of a postmarketing observational study. Circ J 84:101\u2013108","journal-title":"Circ J"},{"key":"1714_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1161\/01.CIR.0000051720.59095.6D","volume":"107","author":"JE Sousa","year":"2003","unstructured":"Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW (2003) Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 107:381\u2013383","journal-title":"Circulation"},{"key":"1714_CR8","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jacc.2011.01.011","volume":"57","author":"G Nakazawa","year":"2011","unstructured":"Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R (2011) The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 57:1314\u20131322","journal-title":"J Am Coll Cardiol"},{"key":"1714_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jcin.2011.05.025","volume":"4","author":"T Inoue","year":"2011","unstructured":"Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI (2011) Vascular inflammation and repair: implication for reendothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 4:1057\u20131066","journal-title":"JACC Cardiovasc Interv"},{"key":"1714_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.amjcard.2009.09.032","volume":"105","author":"T Kubo","year":"2010","unstructured":"Kubo T, Imanishi T, Kashiwagi M, Ikejima H, Tsujioka H, Kuroi A, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Kitabata H, Takarada S, Tanaka A, Mizukoshi M, Akasaka T (2010) Multiple coronary lesion instability in patients with acute myocardial infarction as determined by optical coherence tomography. Am J Cardiol 105:318\u2013322","journal-title":"Am J Cardiol"},{"key":"1714_CR11","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jcin.2018.04.022","volume":"11","author":"S Ariotti","year":"2018","unstructured":"Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens G, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Valgimigli M, HI-TECH Investigators (2018) Effects of ticagrelor, prasugrel, or clopidogrel on endothelial function and other vascular biomarkers: a randomized crossover study. JACC Cardiovasc Interv 11:1576\u20131586","journal-title":"JACC Cardiovasc Interv"},{"key":"1714_CR12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1160\/TH14-12-1068","volume":"114","author":"MR Thomas","year":"2015","unstructured":"Thomas MR, Storey RF (2015) Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost 114:490\u2013497","journal-title":"Thromb Haemost"},{"issue":"21","key":"1714_CR13","doi-asserted-by":"publisher","first-page":"e009600","DOI":"10.1161\/JAHA.118.009600","volume":"7","author":"X An","year":"2018","unstructured":"An X, Jiang G, Cheng C, Lv Z, Liu Y, Wang F (2018) Inhibition of platelets by clopidogrel suppressed Ang II-induced vascular inflammation, oxidative stress, and remodeling. J Am Heart Assoc 7(21):e009600. https:\/\/doi.org\/10.1161\/JAHA.118.009600","journal-title":"J Am Heart Assoc"},{"key":"1714_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/tpj.2012.10","volume":"13","author":"S Martis","year":"2013","unstructured":"Martis S, Peter I, Hulot J-S, Kornreich R, Desnick RJ, Scott SA (2013) Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J 13:369\u2013377","journal-title":"Pharmacogenomics J"},{"key":"1714_CR15","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1161\/CIRCULATIONAHA.107.696732","volume":"119","author":"MJ Price","year":"2009","unstructured":"Price MJ (2009) Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 119:2625\u20132632","journal-title":"Circulation"},{"key":"1714_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.106.621714","volume":"115","author":"T Inoue","year":"2007","unstructured":"Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, Uchida T, Shimizu M, Komoda H, Node K (2007) Mobilization of CD34-positive bone marrow-derived stem cells after coronary stent implantation: impact on restenosis. Circulation 115:553\u2013561","journal-title":"Circulation"},{"key":"1714_CR17","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1253\/circj.CJ-09-0917","volume":"74","author":"K Arao","year":"2010","unstructured":"Arao K, Yasu T, Ohmura N, Tsukamoto Y, Murata M, Kubo N, Umemoto T, Ikeda N, Ako J, Ishikawa S, Kawakami M, Momomura S (2010) Circulating CD34+\/CD133+ progenitor cells in patients with stable angina pectoris undergoing percutaneous coronary interventions. Circ J 74:1929\u20131935","journal-title":"Circ J"},{"key":"1714_CR18","first-page":"17","volume":"18","author":"M Sakuma","year":"2018","unstructured":"Sakuma M, Nasuno T, Abe S, Obi S, Toyoda S, Taguchi I, Sohma R, Inoue K, Nishino S, Node K, Attizzani G, Bezerra H, Costa M, Simon D, Inoue T (2018) Mobilization of progenitor cells and assessment of vessel healing after second generation drug-eluting stenting by optical coherence tomography. Int J Cardiol Heart Vasc 18:17\u201324","journal-title":"Int J Cardiol Heart Vasc"},{"key":"1714_CR19","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1093\/clinchem\/45.12.2136","volume":"45","author":"N Rifai","year":"1999","unstructured":"Rifai N, Tracy RP, Ridker PM (1999) Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 45:2136\u20132141","journal-title":"Clin Chem"},{"key":"1714_CR20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/hr.2014.103","volume":"37","author":"H Tomiyama","year":"2014","unstructured":"Tomiyama H, Yoshida M, Higashi Y, Takase B, Furumoto T, Kario K, Ohya Y, Yamashinasub-group study of FMD-J A (2014) Autonomic nervous activation triggered during induction of reactive hyperemia exerts a greater influence on the measured reactive hyperemia index by peripheral arterial tonometry than on flow-mediated vasodilatation of the brachial artery in patients with hypertension. Hypertens Res 37:914\u2013918","journal-title":"Hypertens Res"},{"key":"1714_CR21","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/sj.clpt.6100139","volume":"81","author":"NA Farid","year":"2007","unstructured":"Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE (2007) Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81:735\u2013741","journal-title":"Clin Pharmacol Ther"},{"key":"1714_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jjcc.2015.07.019","volume":"68","author":"H Ogawa","year":"2016","unstructured":"Ogawa H, Isshiki T, Kimura T, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Tanaka Y, Saito S (2016) Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. J Cardiol 68:29\u201336","journal-title":"J Cardiol"},{"key":"1714_CR23","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1253\/circj.CJ-15-0546","volume":"79","author":"T Nishi","year":"2015","unstructured":"Nishi T, Ariyoshi N, Nakayama T, Fujimoto Y, Sugimoto K, Takahara M, Wakabayashi S, Koshizaka M, Hanaoka H, Kobayashi Y (2015) Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease. Circ J 79:2439\u20132444","journal-title":"Circ J"},{"key":"1714_CR24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00380-019-01499-7","volume":"35","author":"J Shimamatsu","year":"2020","unstructured":"Shimamatsu J, Sasaki KI, Katsuki Y, Kawasaki T, Murasato Y, Ajisaka H, Yokoi H, Tashiro H, Harada A, Hirakawa Y, Ishizaki Y, Ishimatsu T, Kagiyama K, Fukumoto Y, Kakuma T, Ueno T (2020) Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation. Heart Vessels 35:312\u2013322","journal-title":"Heart Vessels"},{"key":"1714_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.atherosclerosis.2006.12.009","volume":"196","author":"A Warnholtz","year":"2008","unstructured":"Warnholtz A, Ostad MA, Velich N, Trautmann C, Schinzel R, Walter U, Munzel T (2008) A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 196:689\u2013695","journal-title":"Atherosclerosis"},{"key":"1714_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijcard.2017.06.099","volume":"248","author":"TK Rudolph","year":"2017","unstructured":"Rudolph TK, Fuchs A, Klinke A, Schlichting A, Friedrichs K, Hellmich M, Mollenhauer M, Schwedhelm E, Baldus S, Rudolph V (2017) Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet\u2013leukocyte interaction in patients with unstable angina pectoris: a randomized controlled trial. Int J Cardiol 248:7\u201313","journal-title":"Int J Cardiol"},{"key":"1714_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz917","author":"B Schnorbus","year":"2020","unstructured":"Schnorbus B, Daiber A, Jurk K, Warnke S, Koenig J, Lackner KJ, M\u00fcnzel T, Gori T (2020) Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehz917","journal-title":"Eur Heart J"},{"key":"1714_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1254\/jphs.08R01CP","volume":"108","author":"T Umemura","year":"2008","unstructured":"Umemura T, Higashi Y (2008) Endothelial progenitor cells: therapeutic target for cardiovascular diseases. J Pharmacol Sci 108:1\u20136","journal-title":"J Pharmacol Sci"},{"key":"1714_CR29","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1253\/circj.CJ-11-1145","volume":"76","author":"CN Fran\u00e7a","year":"2012","unstructured":"Fran\u00e7a CN, Pinheiro LF, Izar MC, Brunialti MK, Salom\u00e3o R, Bianco HT, Kasmas SH, Barbosa SP, de Nucci G, Fonseca FA (2012) Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J 76:729\u2013736","journal-title":"Circ J"},{"key":"1714_CR30","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.atherosclerosis.2006.11.006","volume":"194","author":"M Li","year":"2007","unstructured":"Li M, Yi Z, Ren H, Zhang Yu, Zhu X (2007) Effect of clopidogrel on inflammatory progression of early atherosclerosis in rabbits model. Atherosclerosis 194:348\u2013356","journal-title":"Atherosclerosis"},{"issue":"7","key":"1714_CR31","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0002-9149(02)02606-1","volume":"90","author":"CP Cannon","year":"2002","unstructured":"Cannon CP, CAPRIE Investigators (2002) Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 90(7):760\u2013762","journal-title":"Am J Cardiol"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-020-01714-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-020-01714-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-020-01714-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T03:04:58Z","timestamp":1615259098000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-020-01714-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1714"],"URL":"https:\/\/doi.org\/10.1007\/s00380-020-01714-w","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"type":"print","value":"0910-8327"},{"type":"electronic","value":"1615-2573"}],"subject":[],"published":{"date-parts":[[2020,10,28]]},"assertion":[{"value":"7 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}